Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BFRG Bullfrog AI	$1.25 -2.3%	$1.52	$1.21 ▼ $4.84	$12.90M	0.47	168,094 shs	85,151 shs
ERNA Ernexa Therapeutics	$1.59 -2.2%	$1.99	$1.50 ▼ $28.80	$12.43M	5.42	85,035 shs	67,068 shs
GRI GRI Bio	$1.39 -3.5%	$1.52	$1.10 ▼ $30.43	$3.60M	-1.61	243,626 shs	47,564 shs
TXMD TherapeuticsMD	$1.17 +1.7%	$1.15	$0.70 ▼ $2.44	$13.31M	0.42	23,564 shs	32,873 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BFRG Bullfrog AI	-2.34%	-1.57%	-16.11%	-28.57%	-51.36%
ERNA Ernexa Therapeutics	-2.16%	-6.76%	-19.54%	-52.83%	-93.94%
GRI GRI Bio	-3.47%	+10.32%	-32.85%	-7.33%	-82.79%
TXMD TherapeuticsMD	+1.71%	+9.85%	+1.73%	-22.01%	-27.78%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BFRG Bullfrog AI	1.3748 of 5 stars	0.0	3.0	4.2	2.5	0.0
ERNA Ernexa Therapeutics	0.6635 of 5 stars	0.0	3.0	2.6	1.7	0.0
GRI GRI Bio	2.3538 of 5 stars	3.5	2.0	2.4	0.0	1.3
TXMD TherapeuticsMD	0.391 of 5 stars	0.0	3.0	1.8	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BFRG Bullfrog AI	0.00	N/A	N/A	N/A
ERNA Ernexa Therapeutics	0.00	N/A	N/A	N/A
GRI GRI Bio	3.00	Buy	$22.00	1,482.73% Upside
TXMD TherapeuticsMD	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest GRI, ERNA, TXMD, and BFRG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
6/11/2025	GRI GRI Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/27/2025	GRI GRI Bio	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $34.00

(Data available from 8/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BFRG Bullfrog AI	N/A	N/A	N/A	N/A	$0.22 per share	N/A
ERNA Ernexa Therapeutics	$580K	20.96	N/A	N/A	$0.58 per share	2.73
GRI GRI Bio	N/A	N/A	N/A	N/A	$7.68 per share	N/A
TXMD TherapeuticsMD	$2.56M	5.29	N/A	N/A	$2.36 per share	0.50

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BFRG Bullfrog AI	-$6.99M	-$0.76	N/A	∞	N/A	N/A	-195.35%	-162.37%	N/A
ERNA Ernexa Therapeutics	-$44.54M	-$8.31	N/A	∞	N/A	-7,652.75%	N/A	-682.08%	N/A
GRI GRI Bio	-$8.21M	-$11.56	N/A	N/A	N/A	N/A	-337.46%	-197.01%	N/A
TXMD TherapeuticsMD	-$2.18M	N/A	0.00	∞	N/A	-17.94%	-2.01%	-1.40%	N/A

Latest GRI, ERNA, TXMD, and BFRG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	GRI GRI Bio	-$1.31	-$1.31	N/A	-$1.31	N/A	N/A
8/13/2025	Q2 2025	BFRG Bullfrog AI	N/A	-$0.15	N/A	-$0.15	N/A	$0.03 million
8/13/2025	Q2 2025	ERNA Ernexa Therapeutics	N/A	-$0.61	N/A	-$0.61	N/A	N/A
8/12/2025	Q2 2025	TXMD TherapeuticsMD	N/A	$0.05	N/A	$0.05	N/A	$0.95 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BFRG Bullfrog AI	N/A	N/A	N/A	N/A	N/A
ERNA Ernexa Therapeutics	N/A	N/A	N/A	N/A	N/A
GRI GRI Bio	N/A	N/A	N/A	N/A	N/A
TXMD TherapeuticsMD	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BFRG Bullfrog AI	N/A	3.97	4.87
ERNA Ernexa Therapeutics	N/A	1.81	0.21
GRI GRI Bio	N/A	1.41	1.41
TXMD TherapeuticsMD	N/A	2.89	2.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BFRG Bullfrog AI	0.96%
ERNA Ernexa Therapeutics	70.55%
GRI GRI Bio	33.95%
TXMD TherapeuticsMD	30.74%

Insider Ownership

Company	Insider Ownership
BFRG Bullfrog AI	33.90%
ERNA Ernexa Therapeutics	1.50%
GRI GRI Bio	0.87%
TXMD TherapeuticsMD	2.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BFRG Bullfrog AI	4	10.08 million	6.66 million	Not Optionable
ERNA Ernexa Therapeutics	10	7.67 million	7.26 million	No Data
GRI GRI Bio	1	2.50 million	2.48 million	Not Optionable
TXMD TherapeuticsMD	420	11.57 million	11.31 million	Optionable

GRI, ERNA, TXMD, and BFRG Headlines

Recent News About These Companies

TherapeuticsMD Reports Q2 2025 Financial Results

August 12, 2025 | msn.com

TherapeuticsMD: Q2 Earnings Snapshot

August 12, 2025 | finance.yahoo.com

TherapeuticsMD Announces Second Quarter 2025 Financial Results

August 12, 2025 | businesswire.com

TherapeuticsMD (NASDAQ:TXMD) Stock Price Up 0.5% - Should You Buy?

August 7, 2025 | americanbankingnews.com

TherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors despite daily gains

July 16, 2025 | marketwatch.com

Marlan D. Walker - TXMD | TherapeuticsMD Inc. - Wall Street Journal

June 29, 2025 | wsj.com

Mayne Pharma Files Legal Complaint Against TherapeuticsMD

June 1, 2025 | tipranks.com

TherapeuticsMD Announces First Quarter 2025 Financial Results

May 13, 2025 | businesswire.com

TherapeuticsMD Inc. stock rises Monday, still underperforms market

May 12, 2025 | marketwatch.com

TherapeuticsMD Inc. stock outperforms competitors despite losses on the day

April 8, 2025 | marketwatch.com

TherapeuticsMD Announces Full Year 2024 Financial Results

March 27, 2025 | businesswire.com

TherapeuticsMD, Inc. (TXMD) Latest Press Releases & Corporate News - Yahoo Finance

March 26, 2025 | finance.yahoo.com

TherapeuticsMD Inc’s Stock Drama: Could This Be a Game-Changer for TXMD Investors?

January 7, 2025 | bovnews.comB

TherapeuticsMD Inc (TXMD) Stock: A Deeper Look at Its True Potential

January 3, 2025 | bovnews.comB

TherapeuticsMD Inc. stock remains steady Friday, still outperforms market

December 27, 2024 | marketwatch.com

TherapeuticsMD Inc. stock underperforms Friday when compared to competitors despite daily gains

November 23, 2024 | marketwatch.com

TherapeuticsMD Shifts Focus with Lower Q3 Losses

November 14, 2024 | markets.businessinsider.com

TherapeuticsMD Reports Reduced Losses Amid Strategic Shift

November 14, 2024 | markets.businessinsider.com

TherapeuticsMD Announces Third Quarter 2024 Financial Results

November 13, 2024 | finance.yahoo.com

TherapeuticsMD Inc. stock remains steady Monday, underperforms market

November 12, 2024 | marketwatch.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

GRI, ERNA, TXMD, and BFRG Company Descriptions

Bullfrog AI NASDAQ:BFRG

$1.25 -0.03 (-2.34%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.26 +0.01 (+1.20%)

As of 08/15/2025 07:48 PM Eastern

Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.

Ernexa Therapeutics NASDAQ:ERNA

$1.58 -0.04 (-2.16%)

Closing price 08/15/2025 03:59 PM Eastern

Extended Trading

$1.64 +0.05 (+3.47%)

As of 08/15/2025 07:58 PM Eastern

Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

GRI Bio NASDAQ:GRI

$1.39 -0.05 (-3.47%)

As of 08/15/2025 04:00 PM Eastern

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

TherapeuticsMD NASDAQ:TXMD

$1.17 +0.02 (+1.71%)

Closing price 08/15/2025 03:58 PM Eastern

Extended Trading

$1.14 -0.03 (-2.56%)

As of 08/15/2025 07:44 PM Eastern

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time